TECHNOLOGY

A Novel Target for Antiviral Therapeutics

OVERVIEW

The propagation of many important viruses depends upon the availability of precise ratios of viral proteins as determined by the efficiency of programmed ribosomal frameshifting (PRF). Thus a better understanding of the molecular mechanisms underlying the control of PRF can contribute toward new targets for the rational design of antiviral therapies.

A researcher at the Department of Cell Biology and Molecular Genetics, University of Maryland College Park has developed a novel method for modulating the translational termination of messenger RNA. This will enable the identification and characterization of factors that modulate the termination efficiency and will be important for both understanding the biology of translational termination as well as in identifying new therapeutic agents.

For additional information please contact the Office of Technology Commercialization, University of Maryland. Phone: 301-405-3947. E-mail: otc@umd.edu

CONTACT INFO

UM Ventures
0134 Lee Building
7809 Regents Drive
College Park, MD 20742
Email: umdtechtransfer@umd.edu
Phone: (301) 405-3947 | Fax: (301) 314-9502

Additional Information

INSTITUTION

University of Maryland, College Park

PATENT STATUS

Patent(s) pending

LICENSE STATUS

Contact OTC for licensing information

CATEGORIES

- Vaccines
- Biologics

EXTERNAL RESOURCES

- US Patent 9,206,466

LS-2003-049